Incyte Corporation ($INCY) Stock Forecast: Up 9.1% Today

What is Incyte Corporation?

Incyte Corporation (NASDAQ: INCY) is a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics. The stock showed a strong bullish movement recently. An exclusive option agreement was announced between Incyte and Prelude Therapeutics to advance mutant selective JAK2V617F JH2 inhibitors, indicating potential in treating myeloproliferative neoplasms. Despite concerns over a patent expiry in 2028, Incyte demonstrated strong growth in the third quarter, exceeding revenue expectations due to increased product sales. Strong Q3 earnings and revenue surpasses were attributed to heightened sales of key products like Jakafi and Opzelura, as well as successful new product launches.

Why is Incyte Corporation going up?

INCY stock is up 9.1% on Nov 4, 2025 14:46

• The bullish movement in Incyte's stock is likely due to positive advancements in their partnership with Prelude Therapeutics for potential disease-modifying treatments and the company's robust financial performance in Q3, surpassing revenue expectations and demonstrating growth potential in the face of patent concerns. These factors, combining positive developments and financial success, probably boosted investor optimism and led to the stock's upward trajectory.

INCY Price Chart

INCY Technical Analysis

INCY News

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Incyte ( NASDAQ:INCY ) , Prelude Therapeutics ( NASDAQ:PRLD )

Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms ( MPNs )

https://www.benzinga.com/pressreleases/25/11/g48616261/prelude-therapeutics-announces-exclusive-option-agreement-with-incyte-to-advance-mutant-selective-

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program ...

https://www.globenewswire.com/news-release/2025/11/04/3180168/0/en/Prelude-Therapeutics-Announces-Exclusive-Option-Agreement-with-Incyte-to-Advance-Mutant-Selective-JAK2V617F-JH2-Inhibitors.html

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Incyte ( NASDAQ:INCY )

Incyte Corporation's ( NASDAQ:INCY ) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion. Total revenues increased 20% year over year, primarily driven by a rise in total net product revenues. Total net product revenue was $1.15 billion, representing a ...

https://www.benzinga.com/markets/earnings/25/10/48474772/incyte-delivers-robust-growth-but-2028-patent-expiry-still-looms

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.

https://www.zacks.com/stock/news/2779218/incys-q3-earnings-revenues-beat-estimates-on-higher-product-sales

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 37.7% Today

XRP ($XRP) Crypto Forecast: Up 8.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.0% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.1% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Down 0.4% Today

Duke Energy Corporation (Holding Company) ($DUK) Stock Forecast: Down 0.2% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 9.2% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 8.3% Today

Incyte Corporation Price History

30.06.2025 - INCY Stock was up 5.9%

• INCY stock experienced a strong bullish movement today.
• The bullish trend can be attributed to Incyte reporting better-than-expected Q2 earnings and revenues, driven by strong sales of Jakafi and Opzelura.
• The company's upward revisions in guidance for Jakafi demand and other oncology products have also contributed to the positive market sentiment.
• Investors are optimistic about the company's performance in the upcoming quarters, especially with the success of their key products and new launches driving revenues.

28.09.2025 - INCY Stock was down 5.0%

• The bearish movement in INCY stock today could be attributed to profit-taking by investors ahead of the company's Q3 earnings report.
• Despite expectations of strong performance driven by key products like Jakafi and Opzelura, investors may have been cautious due to uncertainties surrounding new product launches like Niktimvo.
• The anticipation of a potential earnings beat may have already been priced into the stock, leading to a sell-off post-news headlines.
• Market sentiment may have also been influenced by broader industry trends or economic indicators impacting the biopharmaceutical sector.

29.06.2025 - INCY Stock was up 9.1%

• Incyte (INCY) exceeded Q2 earnings and revenue expectations, showcasing a robust performance in the quarter.
• The revenue growth of 16% to $1.22B and EPS of $1.57 compared to a loss of $1.82 YoY contributed to the bullish sentiment.
• Upward revisions in Jakafi guidance to $3-$3.05 billion for 2025, along with positive outlooks on other oncology products, fueled investor optimism.
• The strong performance in Q2, driven by successful products like Jakafi, Opzelura, and new launches, led to increased confidence in Incyte's future prospects, resulting in the bullish market movement.

29.06.2025 - INCY Stock was up 6.0%

• Expectations of a strong Q2 performance with key products like Jakafi, Opzelura, and Niktimvo driving revenues likely contributed to the bullish movement.
• Anticipation of an earnings beat in the upcoming report could have attracted investors to buy INCY stock, leading to the bullish movement.
• Positive sentiment surrounding the company's product portfolio and potential growth prospects might have fueled investor confidence, pushing the stock higher.

26.05.2025 - INCY Stock was up 5.0%

• The FDA approval for the expanded use of Monjuvi in lymphoma is a significant milestone for Incyte, underscoring the company's commitment to developing effective treatments for challenging conditions.
• The approval of Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma creates a new revenue stream for Incyte and strengthens its position in the oncology market.
• The strong bullish movement in INCY stock today is likely influenced by this positive development, as investors react favorably to the company's growth prospects and expanding product portfolio in the competitive biopharmaceutical industry.

04.10.2025 - INCY Stock was up 9.1%

• The bullish movement in Incyte's stock is likely due to positive advancements in their partnership with Prelude Therapeutics for potential disease-modifying treatments and the company's robust financial performance in Q3, surpassing revenue expectations and demonstrating growth potential in the face of patent concerns. These factors, combining positive developments and financial success, probably boosted investor optimism and led to the stock's upward trajectory.

17.09.2025 - INCY Stock was down 5.7%

• The comparison between INCY and ARGX for better value stock might have highlighted weaknesses in INCY's financials or growth prospects, leading to a bearish movement.
• Investors may have reevaluated INCY's position in the market and decided to shift their investments towards other companies with more promising value propositions.
• This assessment could have triggered a sell-off in INCY's stock, driving the bearish movement observed today.
• It is essential for investors to carefully analyze the underlying factors driving such comparisons to make informed decisions about their investment strategies.

11.02.2025 - INCY Stock was down 2.7%

• Positive phase III study results for Opzelura in treating prurigo nodularis may have heightened investor expectations.
• The significant downward movement in INCY's stock suggests the market may have factored in the positive outcomes already, resulting in a sell-off post-announcement.
• Investors seem to be capitalizing on the news by selling for profit, causing a temporary decline in the stock price despite Opzelura's promising efficacy results.

11.02.2025 - INCY Stock was down 5.7%

• INCY is the stock symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
• ASSESSMENT:
• The bearish movement in INCY stock today could be due to profit-taking by investors after a strong positive run following the news of Opzelura's superior efficacy in prurigo nodularis studies.
• Despite the positive data from the phase III studies and the encouraging efficacy of their partnered FDA-approved drug, investors may have been expecting even better results, leading to a sell-off.
• The market might be reacting to concerns about the sustainability of the positive outcomes reported, leading to a temporary dip in the stock price.

10.01.2025 - INCY Stock was down 4.6%

• There was unusual options activity indicating a bullish sentiment among deep-pocketed investors, but it did not result in a positive market movement for Incyte today.
• Incyte reported mixed Q4 earnings with revenue surpassing estimates but earnings falling short, which seemed to drive the bearish movement.
• Despite strong sales of key products in Q4 and a positive outlook for 2025 with upcoming launches, the disappointment from the earnings miss contributed to the stock price decline.
• Investors may be exercising caution regarding the future trajectory of Incyte's stock due to the unexpected earnings results and the need for further clarity on the company's financial performance in the coming quarters.

17.02.2025 - INCY Stock was up 5.1%

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.

29.09.2025 - INCY Stock was up 7.2%

• Incyte Corporation demonstrated robust growth in third-quarter revenue, exceeding consensus estimates and displaying a 20% year-over-year increase in total revenues.
• The strong performance in Q3 was attributed to higher sales figures of key products like Jakafi, Opzelura, and recent launches, indicating positive revenue prospects for the company.
• Despite concerns regarding a patent expiration in 2028, the company's recent quarter results have bolstered investor confidence, resulting in a bullish market trend for INCY stock today.